Durish Ann Dorotheo
Family · Bakersfield, CANPI 1386278927
Payments from drug & device makers
Across 1,036 payments — averaging $24.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$5K
- Livanova USA, Inc.$4K
- AbbVie$4K
- Biogen$1K
- Teva Pharmaceuticals USA, Inc.$1K
- AstraZeneca$781
- plus $10K from 46 others
What the payments were for
- Consulting fees$2,98212%
- Speaking & faculty fees$630%
- Travel & lodging$3,72115%
- Food & beverage$17,61271%
- Education$4942%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Privigen$4,377
- Hizentra$4,377
- VNS Therapy$3,429
- Austedo XR$125
How this compares
$24,871 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 46 | $375,913 |
| NuplazidPimavanserin Tartrate | 18 | $96,813 |
| Aimovig AutoinjectorErenumab-Aooe | 84 | $63,830 |
| RexultiBrexpiprazole | 42 | $60,039 |
| Nurtec OdtRimegepant Sulfate | 43 | $59,394 |
| Emgality PenGalcanezumab-Gnlm | 75 | $51,413 |
| AptiomEslicarbazepine Acetate | 15 | $36,780 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 30 | $23,457 |
| QuliptaAtogepant | 14 | $14,800 |
| KeppraLevetiracetam | 13 | $14,630 |
| UbrelvyUbrogepant | 12 | $13,678 |
| Pregabalin | 403 | $12,202 |
| VimpatLacosamide | 13 | $11,490 |
| NamzaricMemantine Hcl/Donepezil Hcl | 17 | $9,646 |
| Emgality SyringeGalcanezumab-Gnlm | 14 | $9,602 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $458 | $375,91346 claims |
| Acadia Pharmaceuticals IncNuplazid | $777 | $96,81318 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $348 | $60,03942 claims |
| PfizerNurtec Odt | $546 | $59,39443 claims |
| AbbVieQulipta, Ubrelvy, Namzaric | $3,642 | $38,12343 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $297 | $36,78015 claims |
| UCB, Inc.Vimpat | $522 | $11,49013 claims |
| Upsher-smith Laboratories LLCTopiramate | $13 | $1,451160 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Bakersfield
- Jennifer TougasBakersfield$302K
- Ashton ChaseBakersfield$86K
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.